25 XP   0   0   10

Mereo BioPharma Group PLC ADR
Buy, Hold or Sell?

Let's analyse Mereo BioPharma Group PLC ADR together

PenkeI guess you are interested in Mereo BioPharma Group PLC ADR. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Mereo BioPharma Group PLC ADR. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Mereo BioPharma Group PLC ADR

I send you an email if I find something interesting about Mereo BioPharma Group PLC ADR.

Quick analysis of Mereo BioPharma Group PLC ADR (30 sec.)










What can you expect buying and holding a share of Mereo BioPharma Group PLC ADR? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.00
Expected worth in 1 year
$-1.76
How sure are you?
33.3%

+ What do you gain per year?

Total Gains per Share
$-1.76
Return On Investment
-66.8%

For what price can you sell your share?

Current Price per Share
$2.64
Expected price per share
$1.95 - $3.48
How sure are you?
50%

1. Valuation of Mereo BioPharma Group PLC ADR (5 min.)




Live pricePrice per Share (EOD)

$2.64

Intrinsic Value Per Share

$-0.03 - $2.12

Total Value Per Share

$-0.03 - $2.12

2. Growth of Mereo BioPharma Group PLC ADR (5 min.)




Is Mereo BioPharma Group PLC ADR growing?

Current yearPrevious yearGrowGrow %
How rich?$50.5m$61.8m-$11.3m-22.4%

How much money is Mereo BioPharma Group PLC ADR making?

Current yearPrevious yearGrowGrow %
Making money-$29.4m-$34.1m$4.7m16.1%
Net Profit Margin-294.7%-2,269.1%--

How much money comes from the company's main activities?

3. Financial Health of Mereo BioPharma Group PLC ADR (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#479 / 1016

Most Revenue
#303 / 1016

Most Profit
#790 / 1016

Most Efficient
#684 / 1016

What can you expect buying and holding a share of Mereo BioPharma Group PLC ADR? (5 min.)

Welcome investor! Mereo BioPharma Group PLC ADR's management wants to use your money to grow the business. In return you get a share of Mereo BioPharma Group PLC ADR.

What can you expect buying and holding a share of Mereo BioPharma Group PLC ADR?

First you should know what it really means to hold a share of Mereo BioPharma Group PLC ADR. And how you can make/lose money.

Speculation

The Price per Share of Mereo BioPharma Group PLC ADR is $2.64. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Mereo BioPharma Group PLC ADR.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Mereo BioPharma Group PLC ADR, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.00. Based on the TTM, the Book Value Change Per Share is $-0.44 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.19 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Mereo BioPharma Group PLC ADR.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.000.0%0.000.0%-0.24-9.2%-0.31-11.9%-0.26-9.9%
Usd Book Value Change Per Share-0.44-16.7%-0.44-16.7%-0.19-7.1%-0.05-1.8%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.44-16.7%-0.44-16.7%-0.19-7.1%-0.05-1.8%0.000.0%
Usd Price Per Share2.31-2.31-0.75-2.30-1.28-
Price to Earnings Ratio-51,698.18--51,698.18--3.08--10,339.98--5,744.43-
Price-to-Total Gains Ratio-5.24--5.24--4.02-9.06-9.06-
Price to Book Ratio30,143.03-30,143.03-1.70-6,025.04-3,347.24-
Price-to-Total Gains Ratio-5.24--5.24--4.02-9.06-9.06-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.64
Number of shares378
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.44-0.05
Usd Total Gains Per Share-0.44-0.05
Gains per Quarter (378 shares)-166.73-17.66
Gains per Year (378 shares)-666.90-70.64
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-667-6770-71-81
20-1334-13440-141-152
30-2001-20110-212-223
40-2668-26780-283-294
50-3335-33450-353-365
60-4001-40120-424-436
70-4668-46790-494-507
80-5335-53460-565-578
90-6002-60130-636-649
100-6669-66800-706-720

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%1.08.00.011.1%1.08.00.011.1%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%3.06.00.033.3%3.06.00.033.3%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.09.00.0%0.00.09.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%3.06.00.033.3%3.06.00.033.3%

Fundamentals of Mereo BioPharma Group PLC ADR

About Mereo BioPharma Group PLC ADR

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Fundamental data was last updated by Penke on 2024-04-11 15:06:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Mereo BioPharma Group PLC ADR.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Mereo BioPharma Group PLC ADR earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Mereo BioPharma Group PLC ADR to the Biotechnology industry mean.
  • A Net Profit Margin of -294.7% means that $-2.95 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Mereo BioPharma Group PLC ADR:

  • The MRQ is -294.7%. The company is making a huge loss. -2
  • The TTM is -294.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-294.7%TTM-294.7%0.0%
TTM-294.7%YOY-2,269.1%+1,974.5%
TTM-294.7%5Y-3,120.8%+2,826.1%
5Y-3,120.8%10Y-1,602.5%-1,518.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-294.7%-199.6%-95.1%
TTM-294.7%-213.0%-81.7%
YOY-2,269.1%-279.3%-1,989.8%
5Y-3,120.8%-438.4%-2,682.4%
10Y-1,602.5%-605.5%-997.0%
1.1.2. Return on Assets

Shows how efficient Mereo BioPharma Group PLC ADR is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Mereo BioPharma Group PLC ADR to the Biotechnology industry mean.
  • -44.3% Return on Assets means that Mereo BioPharma Group PLC ADR generated $-0.44 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Mereo BioPharma Group PLC ADR:

  • The MRQ is -44.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -44.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-44.3%TTM-44.3%0.0%
TTM-44.3%YOY-38.8%-5.5%
TTM-44.3%5Y-74.7%+30.4%
5Y-74.7%10Y-56.1%-18.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-44.3%-13.5%-30.8%
TTM-44.3%-12.9%-31.4%
YOY-38.8%-11.8%-27.0%
5Y-74.7%-14.1%-60.6%
10Y-56.1%-16.0%-40.1%
1.1.3. Return on Equity

Shows how efficient Mereo BioPharma Group PLC ADR is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Mereo BioPharma Group PLC ADR to the Biotechnology industry mean.
  • -58.3% Return on Equity means Mereo BioPharma Group PLC ADR generated $-0.58 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Mereo BioPharma Group PLC ADR:

  • The MRQ is -58.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -58.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-58.3%TTM-58.3%0.0%
TTM-58.3%YOY-55.3%-3.0%
TTM-58.3%5Y-37.1%-21.2%
5Y-37.1%10Y-43.7%+6.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-58.3%-16.9%-41.4%
TTM-58.3%-16.1%-42.2%
YOY-55.3%-15.1%-40.2%
5Y-37.1%-19.9%-17.2%
10Y-43.7%-20.9%-22.8%

1.2. Operating Efficiency of Mereo BioPharma Group PLC ADR.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Mereo BioPharma Group PLC ADR is operating .

  • Measures how much profit Mereo BioPharma Group PLC ADR makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Mereo BioPharma Group PLC ADR to the Biotechnology industry mean.
  • An Operating Margin of -250.2% means the company generated $-2.50  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Mereo BioPharma Group PLC ADR:

  • The MRQ is -250.2%. The company is operating very inefficient. -2
  • The TTM is -250.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-250.2%TTM-250.2%0.0%
TTM-250.2%YOY-2,891.1%+2,641.0%
TTM-250.2%5Y3,926.6%-4,176.7%
5Y3,926.6%10Y2,331.8%+1,594.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-250.2%-295.1%+45.0%
TTM-250.2%-225.8%-24.4%
YOY-2,891.1%-288.4%-2,602.7%
5Y3,926.6%-477.4%+4,404.0%
10Y2,331.8%-625.6%+2,957.4%
1.2.2. Operating Ratio

Measures how efficient Mereo BioPharma Group PLC ADR is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 3.71 means that the operating costs are $3.71 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Mereo BioPharma Group PLC ADR:

  • The MRQ is 3.714. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.714. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.714TTM3.7140.000
TTM3.714YOY30.153-26.440
TTM3.7145Y-38.575+42.288
5Y-38.57510Y-22.963-15.612
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7143.090+0.624
TTM3.7143.264+0.450
YOY30.1533.783+26.370
5Y-38.5755.679-44.254
10Y-22.9637.894-30.857

1.3. Liquidity of Mereo BioPharma Group PLC ADR.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Mereo BioPharma Group PLC ADR is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.72 means the company has $6.72 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Mereo BioPharma Group PLC ADR:

  • The MRQ is 6.721. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.721. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.721TTM6.7210.000
TTM6.721YOY2.518+4.204
TTM6.7215Y4.330+2.392
5Y4.33010Y8.682-4.352
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.7213.914+2.807
TTM6.7214.220+2.501
YOY2.5185.388-2.870
5Y4.3306.045-1.715
10Y8.6826.406+2.276
1.3.2. Quick Ratio

Measures if Mereo BioPharma Group PLC ADR is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Mereo BioPharma Group PLC ADR to the Biotechnology industry mean.
  • A Quick Ratio of 6.45 means the company can pay off $6.45 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Mereo BioPharma Group PLC ADR:

  • The MRQ is 6.447. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.447. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.447TTM6.4470.000
TTM6.447YOY4.462+1.985
TTM6.4475Y4.586+1.861
5Y4.58610Y8.792-4.206
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.4473.572+2.875
TTM6.4473.998+2.449
YOY4.4625.390-0.928
5Y4.5865.969-1.383
10Y8.7926.287+2.505

1.4. Solvency of Mereo BioPharma Group PLC ADR.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Mereo BioPharma Group PLC ADR assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Mereo BioPharma Group PLC ADR to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.24 means that Mereo BioPharma Group PLC ADR assets are financed with 24.0% credit (debt) and the remaining percentage (100% - 24.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Mereo BioPharma Group PLC ADR:

  • The MRQ is 0.240. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.240. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.240TTM0.2400.000
TTM0.240YOY0.298-0.058
TTM0.2405Y0.523-0.283
5Y0.52310Y0.402+0.121
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2400.336-0.096
TTM0.2400.334-0.094
YOY0.2980.269+0.029
5Y0.5230.366+0.157
10Y0.4020.390+0.012
1.4.2. Debt to Equity Ratio

Measures if Mereo BioPharma Group PLC ADR is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Mereo BioPharma Group PLC ADR to the Biotechnology industry mean.
  • A Debt to Equity ratio of 31.6% means that company has $0.32 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Mereo BioPharma Group PLC ADR:

  • The MRQ is 0.316. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.316. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.316TTM0.3160.000
TTM0.316YOY0.424-0.108
TTM0.3165Y0.465-0.149
5Y0.46510Y0.452+0.013
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3160.382-0.066
TTM0.3160.396-0.080
YOY0.4240.335+0.089
5Y0.4650.434+0.031
10Y0.4520.465-0.013

2. Market Valuation of Mereo BioPharma Group PLC ADR

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Mereo BioPharma Group PLC ADR generates.

  • Above 15 is considered overpriced but always compare Mereo BioPharma Group PLC ADR to the Biotechnology industry mean.
  • A PE ratio of -51,698.18 means the investor is paying $-51,698.18 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Mereo BioPharma Group PLC ADR:

  • The EOD is -59,083.634. Based on the earnings, the company is expensive. -2
  • The MRQ is -51,698.180. Based on the earnings, the company is expensive. -2
  • The TTM is -51,698.180. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-59,083.634MRQ-51,698.180-7,385.454
MRQ-51,698.180TTM-51,698.1800.000
TTM-51,698.180YOY-3.076-51,695.104
TTM-51,698.1805Y-10,339.978-41,358.201
5Y-10,339.97810Y-5,744.432-4,595.546
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-59,083.634-2.259-59,081.375
MRQ-51,698.180-2.569-51,695.611
TTM-51,698.180-2.664-51,695.516
YOY-3.076-4.120+1.044
5Y-10,339.978-6.258-10,333.720
10Y-5,744.432-6.171-5,738.261
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Mereo BioPharma Group PLC ADR:

  • The EOD is -80,783.182. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -70,685.284. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -70,685.284. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-80,783.182MRQ-70,685.284-10,097.898
MRQ-70,685.284TTM-70,685.2840.000
TTM-70,685.284YOY-2.709-70,682.575
TTM-70,685.2845Y-14,150.914-56,534.370
5Y-14,150.91410Y-7,861.619-6,289.295
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-80,783.182-2.924-80,780.258
MRQ-70,685.284-3.246-70,682.038
TTM-70,685.284-3.488-70,681.796
YOY-2.709-5.620+2.911
5Y-14,150.914-8.315-14,142.599
10Y-7,861.619-8.826-7,852.793
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Mereo BioPharma Group PLC ADR is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 30,143.03 means the investor is paying $30,143.03 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Mereo BioPharma Group PLC ADR:

  • The EOD is 34,449.183. Based on the equity, the company is expensive. -2
  • The MRQ is 30,143.035. Based on the equity, the company is expensive. -2
  • The TTM is 30,143.035. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD34,449.183MRQ30,143.035+4,306.148
MRQ30,143.035TTM30,143.0350.000
TTM30,143.035YOY1.700+30,141.335
TTM30,143.0355Y6,025.035+24,118.000
5Y6,025.03510Y3,347.242+2,677.793
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD34,449.1831.851+34,447.332
MRQ30,143.0352.090+30,140.945
TTM30,143.0352.095+30,140.940
YOY1.7002.844-1.144
5Y6,025.0353.466+6,021.569
10Y3,347.2423.815+3,343.427
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Mereo BioPharma Group PLC ADR.

3.1. Institutions holding Mereo BioPharma Group PLC ADR

Institutions are holding 61.414% of the shares of Mereo BioPharma Group PLC ADR.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Rubric Capital Management LP9.66290.649613552997193687716.674
2023-12-31Soleus Capital Management, L.P.6.97112.506197774191000001.0333
2023-12-31Mangrove Partners6.24061.36588752893322134658.2359
2023-12-31Rock Springs Capital Management LP5.69230.45479838513073704.004
2023-12-31Suvretta Capital Management, LLC5.25520.7698737083864000.0869
2023-12-31683 Capital Management LLC4.42041.17362000002000003.3333
2023-12-31Alkeon Capital Management, LLC3.02170.0219423810050000013.3758
2023-12-31Goldman Sachs Group Inc2.88570.000840473442023672100
2023-12-31Tejara Capital Ltd2.64743.5927371312949812815.4939
2023-12-31Clearline Capital LP2.37190.470933267182239957.2193
2023-12-31Adage Capital Partners Gp LLC1.88940.012726500001850000231.25
2023-09-30Citadel Advisors Llc1.59880.0006224242547398226.8022
2023-12-31Renaissance Technologies Corp1.28190.00641798009704394.0773
2023-12-31abrdn PLC1.10590.0078155108215510820
2023-12-31Millennium Management LLC1.00550.0014141031716673213.4074
2023-12-31Dafna Capital Management LLC0.55530.4311778813-183700-19.0855
2023-12-31Monaco Asset Management0.48230.45996764948076513.5573
2023-12-31Neos Investment Management, LLC0.25090.077351905310577751.4929
2023-12-31Tidal Investments LLC.0.22770.0172319390-12524-3.7733
2023-12-31Two Sigma Investments LLC0.22180.0017311060168458118.1316
Total 57.788712.020481052784+13493599+16.6%

3.2. Funds holding Mereo BioPharma Group PLC ADR

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29abrdn Healthcare Investors0.39960.2126560468-264565-32.0672
2024-03-28Tema Obesity & Cardiometabolic ETF0.32642.537745780000
2024-01-31Alger LIfe Sciences Innovation Composite0.19114.5839267989165458161.3736
2024-02-29abrdn Life Sciences Investors0.18310.2207256841-119639-31.7783
2024-03-28Tema Oncology ETF0.10882.640515255022431.4923
2024-02-29Fidelity Nasdaq Composite Index0.06890.00249663000
2024-02-29Arctic Aurora Biotech Select N NOK Acc0.03721.0228521601000.1921
2023-12-31PMC Diversified Equity0.03360.014247169471690
2023-12-31Vanguard US Opportunities Ins USD Acc0.03140.00814400000
2023-12-31Forefront Tiresias Strategy0.02381.721833424-27225-44.8894
2024-01-31JHVIT Health Sciences I0.02020.040128300283000
2024-01-31JHFunds2 Health Sciences NAV0.02010.040228200282000
2024-02-29EQ/T. Rowe Price Health Sciences IB0.0140.03921960000
2024-03-28ActivePassive International Equity ETF0.01210.0199169411230.7314
2023-12-31Acadian Non-US Small-Cap Developed Eqty0.01160.001716327163270
2023-12-31PRIMECAP Odyssey Aggressive Growth0.00710.000310000-25000-71.4286
2024-02-29LUX IM Global Medtech HX0.00160.0038220000
2023-12-31Northern Small Cap Core K0.00070.0005100700
2023-12-31NT Quality SCC US Fund - L0.00040.000661900
2023-12-31NT Quality Small Cap Core0.00040.000661900
Total 1.492113.11162092844-148509-7.1%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Mereo BioPharma Group PLC ADR compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.441-0.4410%-0.186-58%-0.047-89%0.000-5180066%
Book Value Per Share--0.0000.0000%0.441-100%0.250-100%0.357-100%
Current Ratio--6.7216.7210%2.518+167%4.330+55%8.682-23%
Debt To Asset Ratio--0.2400.2400%0.298-19%0.523-54%0.402-40%
Debt To Equity Ratio--0.3160.3160%0.424-25%0.465-32%0.452-30%
Dividend Per Share----0%-0%-0%-0%
Eps--0.0000.0000%-0.244+545604%-0.314+701896%-0.263+587437%
Free Cash Flow Per Share--0.0000.0000%-0.277+847134%-0.170+518834%-0.182+556113%
Free Cash Flow To Equity Per Share--0.0000.0000%-0.282+1371780%-0.019+90086%0.002-101%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--2.117--------
Intrinsic Value_10Y_min---0.027--------
Intrinsic Value_1Y_max---0.038--------
Intrinsic Value_1Y_min---0.129--------
Intrinsic Value_3Y_max--0.078--------
Intrinsic Value_3Y_min---0.280--------
Intrinsic Value_5Y_max--0.422--------
Intrinsic Value_5Y_min---0.313--------
Market Cap370241541.120-411345%1523338557510.0001523338557510.0000%105182256.000+1448185%304926039122.736+400%169403355068.187+799%
Net Profit Margin---2.947-2.9470%-22.691+670%-31.208+959%-16.025+444%
Operating Margin---2.502-2.5020%-28.911+1056%39.266-106%23.318-111%
Operating Ratio--3.7143.7140%30.153-88%-38.575+1139%-22.963+718%
Pb Ratio34449.183+13%30143.03530143.0350%1.700+1772907%6025.035+400%3347.242+801%
Pe Ratio-59083.634-14%-51698.180-51698.1800%-3.076-100%-10339.978-80%-5744.432-89%
Price Per Share2.640+13%2.3102.3100%0.750+208%2.304+0%1.280+80%
Price To Free Cash Flow Ratio-80783.182-14%-70685.284-70685.2840%-2.709-100%-14150.914-80%-7861.619-89%
Price To Total Gains Ratio-5.985-14%-5.237-5.2370%-4.025-23%9.056-158%9.056-158%
Quick Ratio--6.4476.4470%4.462+44%4.586+41%8.792-27%
Return On Assets---0.443-0.4430%-0.388-12%-0.747+69%-0.561+27%
Return On Equity---0.583-0.5830%-0.553-5%-0.371-36%-0.437-25%
Total Gains Per Share---0.441-0.4410%-0.186-58%-0.047-89%0.000-5180066%
Usd Book Value--50537000.00050537000.0000%61868000.000-18%45138400.000+12%55749127.667-9%
Usd Book Value Change Per Share---0.441-0.4410%-0.186-58%-0.047-89%0.000-5180066%
Usd Book Value Per Share--0.0000.0000%0.441-100%0.250-100%0.357-100%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.0000.0000%-0.244+545604%-0.314+701896%-0.263+587437%
Usd Free Cash Flow---21551000.000-21551000.0000%-38830000.000+80%-28092800.000+30%-25053689.222+16%
Usd Free Cash Flow Per Share--0.0000.0000%-0.277+847134%-0.170+518834%-0.182+556113%
Usd Free Cash Flow To Equity Per Share--0.0000.0000%-0.282+1371780%-0.019+90086%0.002-101%
Usd Market Cap370241541.120-411345%1523338557510.0001523338557510.0000%105182256.000+1448185%304926039122.736+400%169403355068.187+799%
Usd Price Per Share2.640+13%2.3102.3100%0.750+208%2.304+0%1.280+80%
Usd Profit---29466000.000-29466000.0000%-34196000.000+16%-49881800.000+69%-40090670.444+36%
Usd Revenue--10000000.00010000000.0000%1507000.000+564%9648400.000+4%4995189.556+100%
Usd Total Gains Per Share---0.441-0.4410%-0.186-58%-0.047-89%0.000-5180066%
 EOD+3 -5MRQTTM+0 -0YOY+21 -125Y+21 -1210Y+16 -17

4.2. Fundamental Score

Let's check the fundamental score of Mereo BioPharma Group PLC ADR based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-59,083.634
Price to Book Ratio (EOD)Between0-134,449.183
Net Profit Margin (MRQ)Greater than0-2.947
Operating Margin (MRQ)Greater than0-2.502
Quick Ratio (MRQ)Greater than16.447
Current Ratio (MRQ)Greater than16.721
Debt to Asset Ratio (MRQ)Less than10.240
Debt to Equity Ratio (MRQ)Less than10.316
Return on Equity (MRQ)Greater than0.15-0.583
Return on Assets (MRQ)Greater than0.05-0.443
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Mereo BioPharma Group PLC ADR based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.803
Ma 20Greater thanMa 502.994
Ma 50Greater thanMa 1003.341
Ma 100Greater thanMa 2003.014
OpenGreater thanClose2.620
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Inventory  -11,9777,339-4,6382,818-1,820-852-2,6723,9191,247
Accumulated Other Comprehensive Income  47,31985,906133,2253,670136,8951,017137,912-155,397-17,485



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets66,499
Total Liabilities15,962
Total Stockholder Equity50,537
 As reported
Total Liabilities 15,962
Total Stockholder Equity+ 50,537
Total Assets = 66,499

Assets

Total Assets66,499
Total Current Assets63,760
Long-term Assets2,739
Total Current Assets
Cash And Cash Equivalents 57,421
Net Receivables 3,732
Inventory 1,247
Other Current Assets 1,360
Total Current Assets  (as reported)63,760
Total Current Assets  (calculated)63,760
+/-0
Long-term Assets
Property Plant Equipment 1,650
Intangible Assets 1,089
Long-term Assets  (as reported)2,739
Long-term Assets  (calculated)2,739
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities9,486
Long-term Liabilities6,476
Total Stockholder Equity50,537
Total Current Liabilities
Short-term Debt 652
Accounts payable 2,346
Other Current Liabilities 30
Total Current Liabilities  (as reported)9,486
Total Current Liabilities  (calculated)3,028
+/- 6,458
Long-term Liabilities
Long term Debt 4,394
Capital Lease Obligations 1,558
Long-term Liabilities Other 764
Long-term Liabilities  (as reported)6,476
Long-term Liabilities  (calculated)6,716
+/- 240
Total Stockholder Equity
Common Stock2,775
Retained Earnings -419,630
Accumulated Other Comprehensive Income -17,485
Other Stockholders Equity 484,877
Total Stockholder Equity (as reported)50,537
Total Stockholder Equity (calculated)50,537
+/-0
Other
Capital Stock2,775
Cash and Short Term Investments 57,421
Common Stock Shares Outstanding 659,453,921
Current Deferred Revenue6,458
Liabilities and Stockholders Equity 66,499
Net Debt -51,469
Net Invested Capital 54,931
Net Working Capital 54,274
Property Plant and Equipment Gross 2,450
Short Long Term Debt Total 5,952



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
> Total Assets 
107,296
86,765
96,335
67,276
86,449
62,947
126,417
88,078
66,499
66,49988,078126,41762,94786,44967,27696,33586,765107,296
   > Total Current Assets 
81,279
60,778
63,177
34,495
30,435
29,726
99,323
62,131
63,760
63,76062,13199,32329,72630,43534,49563,17760,77881,279
       Cash And Cash Equivalents 
79,682
53,578
50,045
25,042
16,347
23,469
94,296
56,334
57,421
57,42156,33494,29623,46916,34725,04250,04553,57879,682
       Short-term Investments 
0
0
2,500
2,500
544
547
569
51,104
0
051,1045695475442,5002,50000
       Net Receivables 
1,343
6,098
8,661
5,886
11,977
4,638
1,820
2,672
3,732
3,7322,6721,8204,63811,9775,8868,6616,0981,343
       Other Current Assets 
254
55,022
4,471
1,360
14,088
6,257
5,027
5,797
1,360
1,3605,7975,0276,25714,0881,3604,47155,022254
   > Long-term Assets 
26,017
25,987
33,159
32,781
56,014
33,221
27,094
25,947
2,739
2,73925,94727,09433,22156,01432,78133,15925,98726,017
       Property Plant Equipment 
205
174
153
149
11,558
1,573
2,530
1,831
1,650
1,6501,8312,5301,57311,558149153174205
       Intangible Assets 
25,813
25,813
33,005
32,632
44,456
31,648
24,564
24,116
1,089
1,08924,11624,56431,64844,45632,63233,00525,81325,813
       Other Assets 
0
0
0
0
0
0
0
0
0
000000000
> Total Liabilities 
5,757
7,508
33,852
34,506
46,193
77,918
38,415
26,210
15,962
15,96226,21038,41577,91846,19334,50633,8527,5085,757
   > Total Current Liabilities 
2,818
3,209
9,618
16,178
29,878
8,565
12,541
24,677
9,486
9,48624,67712,5418,56529,87816,1789,6183,2092,818
       Short-term Debt 
0
0
1,940
6,838
17,725
636
622
11,551
652
65211,55162263617,7256,8381,94000
       Short Long Term Debt 
0
0
1,940
6,838
15,139
0
0
11,085
0
011,0850015,1396,8381,94000
       Accounts payable 
2,818
3,209
3,024
4,570
6,352
3,333
2,285
3,078
2,346
2,3463,0782,2853,3336,3524,5703,0243,2092,818
       Other Current Liabilities 
578
2,214
4,817
4,947
354
4,596
1,269
10,048
30
3010,0481,2694,5963544,9474,8172,214578
   > Long-term Liabilities 
2,939
4,299
24,234
18,328
16,315
69,353
25,874
1,533
6,476
6,4761,53325,87469,35316,31518,32824,2344,2992,939
       Long term Debt Total 
0
3,127
18,813
14,647
14,691
0
0
0
0
000014,69114,64718,8133,1270
       Other Liabilities 
141
1,172
5,422
3,681
1,624
52,053
9,736
311
0
03119,73652,0531,6243,6815,4221,172141
> Total Stockholder Equity
101,539
79,257
62,483
32,771
40,256
-14,971
88,002
61,868
50,537
50,53761,86888,002-14,97140,25632,77162,48379,257101,539
   Common Stock
59
193
213
214
294
1,017
1,755
1,875
2,775
2,7751,8751,7551,01729421421319359
   Retained Earnings -419,630-331,164-296,968-309,693-146,065-111,221-79,316-33,579-12,189
   Accumulated Other Comprehensive Income 
-11
12,668
23,359
25,593
47,319
133,225
136,895
137,912
-17,485
-17,485137,912136,895133,22547,31925,59323,35912,668-11
   Capital Surplus 
26,213
99,975
118,227
118,492
121,684
0
0
0
0
0000121,684118,492118,22799,97526,213
   Treasury Stock000000000
   Other Stockholders Equity 
113,669
99,975
118,227
118,185
138,708
160,480
246,320
253,245
484,877
484,877253,245246,320160,480138,708118,185118,22799,975113,669



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue10,000
Cost of Revenue-2,574
Gross Profit7,4267,426
 
Operating Income (+$)
Gross Profit7,426
Operating Expense-34,562
Operating Income-28,416-27,136
 
Operating Expense (+$)
Research Development17,418
Selling General Administrative18,424
Selling And Marketing Expenses-
Operating Expense34,56235,842
 
Net Interest Income (+$)
Interest Income2,131
Interest Expense-2,881
Other Finance Cost-0
Net Interest Income-750
 
Pretax Income (+$)
Operating Income-28,416
Net Interest Income-750
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-29,998-26,304
EBIT - interestExpense = -27,896
-29,998
-26,585
Interest Expense2,881
Earnings Before Interest and Taxes (EBIT)-25,015-27,117
Earnings Before Interest and Taxes (EBITDA)-23,954
 
After tax Income (+$)
Income Before Tax-29,998
Tax Provision--532
Net Income From Continuing Ops-29,466-29,466
Net Income-29,466
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses37,136
Total Other Income/Expenses Net-2,112750
 

Technical Analysis of Mereo BioPharma Group PLC ADR
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Mereo BioPharma Group PLC ADR. The general trend of Mereo BioPharma Group PLC ADR is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Mereo BioPharma Group PLC ADR's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Mereo BioPharma Group PLC ADR.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.859 < 3.43 < 3.48.

The bearish price targets are: 2.31 > 1.97 > 1.95.

Tweet this
Mereo BioPharma Group PLC ADR Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Mereo BioPharma Group PLC ADR. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Mereo BioPharma Group PLC ADR Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Mereo BioPharma Group PLC ADR. The current macd is -0.19077929.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Mereo BioPharma Group PLC ADR price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Mereo BioPharma Group PLC ADR. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Mereo BioPharma Group PLC ADR price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Mereo BioPharma Group PLC ADR Daily Moving Average Convergence/Divergence (MACD) ChartMereo BioPharma Group PLC ADR Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Mereo BioPharma Group PLC ADR. The current adx is 29.40.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Mereo BioPharma Group PLC ADR shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Mereo BioPharma Group PLC ADR Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Mereo BioPharma Group PLC ADR. The current sar is 3.04397958.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Mereo BioPharma Group PLC ADR Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Mereo BioPharma Group PLC ADR. The current rsi is 31.80. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Mereo BioPharma Group PLC ADR Daily Relative Strength Index (RSI) ChartMereo BioPharma Group PLC ADR Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Mereo BioPharma Group PLC ADR. The current phase is Oversold in neutral market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Mereo BioPharma Group PLC ADR price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Mereo BioPharma Group PLC ADR Daily Stochastic Oscillator ChartMereo BioPharma Group PLC ADR Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Mereo BioPharma Group PLC ADR. The current cci is -109.30690432.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Mereo BioPharma Group PLC ADR Daily Commodity Channel Index (CCI) ChartMereo BioPharma Group PLC ADR Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Mereo BioPharma Group PLC ADR. The current cmo is -43.43340574.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Mereo BioPharma Group PLC ADR Daily Chande Momentum Oscillator (CMO) ChartMereo BioPharma Group PLC ADR Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Mereo BioPharma Group PLC ADR. The current willr is -87.95811518.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Mereo BioPharma Group PLC ADR Daily Williams %R ChartMereo BioPharma Group PLC ADR Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Mereo BioPharma Group PLC ADR.

Mereo BioPharma Group PLC ADR Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Mereo BioPharma Group PLC ADR. The current atr is 0.18745014.

Mereo BioPharma Group PLC ADR Daily Average True Range (ATR) ChartMereo BioPharma Group PLC ADR Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Mereo BioPharma Group PLC ADR. The current obv is 196,655,766.

Mereo BioPharma Group PLC ADR Daily On-Balance Volume (OBV) ChartMereo BioPharma Group PLC ADR Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Mereo BioPharma Group PLC ADR. The current mfi is 9.91746476.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Mereo BioPharma Group PLC ADR Daily Money Flow Index (MFI) ChartMereo BioPharma Group PLC ADR Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Mereo BioPharma Group PLC ADR.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-04BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-22RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-18RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Mereo BioPharma Group PLC ADR Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Mereo BioPharma Group PLC ADR based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.803
Ma 20Greater thanMa 502.994
Ma 50Greater thanMa 1003.341
Ma 100Greater thanMa 2003.014
OpenGreater thanClose2.620
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Mereo BioPharma Group PLC ADR with someone you think should read this too:
  • Are you bullish or bearish on Mereo BioPharma Group PLC ADR? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Mereo BioPharma Group PLC ADR? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Mereo BioPharma Group PLC ADR

I send you an email if I find something interesting about Mereo BioPharma Group PLC ADR.


Comments

How you think about this?

Leave a comment

Stay informed about Mereo BioPharma Group PLC ADR.

Receive notifications about Mereo BioPharma Group PLC ADR in your mailbox!